Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 642804, 16 pages
http://dx.doi.org/10.1155/2010/642804
Review Article
Prospects for the Use of Artificial Chromosomes and Minichromosome-Like Episomes in Gene Therapy
1Departamento de Biología Molecular, Universidad Autónoma de Madrid, 28049 Madrid, Spain
2Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), C/Nicolás Cabrera 1, Universidad Autónoma de Madrid, 28049 Madrid, Spain
3U-748, Area de Neurogenética, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Spain
Received 19 February 2010; Revised 2 June 2010; Accepted 5 July 2010
Academic Editor: Rudi Beyaert
Copyright © 2010 Sara Pérez-Luz and Javier Díaz-Nido. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- Y. Dai, E. M. Schwarz, D. Gu, W.-W. Zhang, N. Sarvetnick, and I. M. Verma, “Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1401–1405, 1995. View at Publisher · View at Google Scholar · View at Scopus
- P. R. Lowenstein, R. J. Mandel, W.-D. Xiong, K. Kroeger, and M. G. Castro, “Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions,” Current Gene Therapy, vol. 7, no. 5, pp. 347–360, 2007. View at Publisher · View at Google Scholar · View at Scopus
- S. Kochanek, P. R. Clemens, K. Mitani, H.-H. Chen, S. Chan, and C. T. Caskey, “A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 5731–5736, 1996. View at Google Scholar · View at Scopus
- S. Kochanek, G. Schiedner, and C. Volpers, “High-capacity 'gutless' adenoviral vectors,” Current Opinion in Molecular Therapeutics, vol. 3, no. 5, pp. 454–463, 2001. View at Google Scholar · View at Scopus
- P. R. Lowenstein, C. E. Thomas, and C. E. Thomas, “High-capacity, helper-dependent, "gutless" adenoviral vectors for gene transfer into brain,” Methods in Enzymology, vol. 346, pp. 292–311, 2002. View at Publisher · View at Google Scholar · View at Scopus
- G. Palù, C. Parolin, Y. Takeuchi, and M. Pizzato, “Progress with retroviral gene vectors,” Reviews in Medical Virology, vol. 10, no. 3, pp. 185–202, 2000. View at Publisher · View at Google Scholar · View at Scopus
- Z. Li, J. Düllmann, and J. Düllmann, “Murine leukemia induced by retroviral gene marking,” Science, vol. 296, no. 5567, p. 497, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- C. E. Thomas, A. Ehrhardt, and M. A. Kay, “Progress and problems with the use of viral vectors for gene therapy,” Nature Reviews Genetics, vol. 4, no. 5, pp. 346–358, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- E. Check, “Regulators split on gene therapy as patient shows signs of cancer,” Nature, vol. 419, no. 6907, pp. 545–546, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- L. Naldini, U. Blömer, and U. Blömer, “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector,” Science, vol. 272, no. 5259, pp. 263–267, 1996. View at Google Scholar · View at Scopus
- J. Reiser, G. Harmison, S. Kluepfel-Stahl, R. O. Brady, S. Karlsson, and M. Schubert, “Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 26, pp. 15266–15271, 1996. View at Google Scholar · View at Scopus
- D. Pannell, C. S. Osborne, and C. S. Osborne, “Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code,” EMBO Journal, vol. 19, no. 21, pp. 5884–5894, 2000. View at Google Scholar · View at Scopus
- R. Jaenisch, “Transgenic animals,” Science, vol. 240, no. 4858, pp. 1468–1474, 1988. View at Google Scholar · View at Scopus
- D. D. Pittman, E. M. Alderman, K. N. Tomkinson, J. H. Wang, A. R. Giles, and R. J. Kaufman, “Biochemical, immunological, and in vivo functional characterization of B- domain-deleted factor VIII,” Blood, vol. 81, no. 11, pp. 2925–2935, 1993. View at Google Scholar · View at Scopus
- C. Huxley, “Exploring gene function: use of yeast artificial chromosome transgenesis,” Methods, vol. 14, no. 2, pp. 199–210, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. P. Sarsero, L. Li, and L. Li, “Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic mice,” Mammalian Genome, vol. 15, no. 5, pp. 370–382, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- G. Brem, U. Besenfelder, B. Aigner, M. Muller, I. Liebl, G. Schutz, and L. Montoliu, “YAC transgenesis in farm animals: rescue of albinism in rabbits,” Molecular Reproduction and Development, vol. 44, no. 1, pp. 56–62, 1996. View at Publisher · View at Google Scholar · View at Scopus
- P. Giraldo and L. Montoliu, “Size matters: use of YACs, BACs and PACs in transgenic animals,” Transgenic Research, vol. 10, no. 2, pp. 83–103, 2001. View at Publisher · View at Google Scholar · View at Scopus
- M. A. Pook, S. Al-Mahdawi, and S. Al-Mahdawi, “Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis,” Neurogenetics, vol. 3, no. 4, pp. 185–193, 2001. View at Publisher · View at Google Scholar · View at Scopus
- P. N. Moreira, J. Pozueta, M. Pérez-Crespo, F. Valdivieso, A. Gutiérrez-Adán, and L. Montoliu, “Improving the generation of genomic-type transgenic mice by ICSI,” Transgenic Research, vol. 16, no. 2, pp. 163–168, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- A. L. Manson, A. E. O. Trezise, and A. E. O. Trezise, “Complementation of null CF mice with a human CFTR YAC transgene,” EMBO Journal, vol. 16, no. 14, pp. 4238–4249, 1997. View at Publisher · View at Google Scholar · View at Scopus
- J. G. Hodgson, D. J. Smith, and D. J. Smith, “Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype,” Human Molecular Genetics, vol. 5, no. 12, pp. 1875–1885, 1996. View at Google Scholar · View at Scopus
- N. G. Copeland, N. A. Jenkins, and D. L. Court, “Recombineering: a powerful new tool for mouse functional genomics,” Nature Reviews Genetics, vol. 2, no. 10, pp. 769–779, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. P. P. Muyrers, Y. Zhang, and A. F. Stewart, “Techniques: recombinogenic engineering—new options for cloning and manipulating DNA,” Trends in Biochemical Sciences, vol. 26, no. 5, pp. 325–331, 2001. View at Publisher · View at Google Scholar · View at Scopus
- K. Narayanan, R. Williamson, Y. Zhang, A. F. Stewart, and P. A. Ioannou, “Efficient and precise engineering of a 200 kb β-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system,” Gene Therapy, vol. 6, no. 3, pp. 442–447, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- I. Poser, M. Sarov, and M. Sarov, “BAC TransgeneOmics: a high-throughput method for exploration of protein function in mammals,” Nature Methods, vol. 5, no. 5, pp. 409–415, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- K. H. A. Choo, “Centromere DNA dynamics: latent centromeres and neocentrome formation,” American Journal of Human Genetics, vol. 61, no. 6, pp. 1225–1233, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- D. M. Kurnit and J. J. Maio, “Variable satellite DNA's in the African green monkey Cercopithecus aethiops,” Chromosoma, vol. 45, no. 4, pp. 387–400, 1974. View at Google Scholar · View at Scopus
- S. S. Potter and R. S. Jones, “Unusual domains of human alphoid satellite DNA with contiguous non-satellite sequences: sequence analysis of a junction region,” Nucleic Acids Research, vol. 11, no. 10, pp. 3137–3153, 1983. View at Google Scholar · View at Scopus
- H. Rosenberg, M. Singer, and M. Rosenberg, “Highly reiterated sequences of SIMIANSIMIANSIMIANSIMIANSIMIAN,” Science, vol. 200, no. 4340, pp. 394–402, 1978. View at Google Scholar · View at Scopus
- R. E. Thayer, M. F. Singer, and T. F. McCutchan, “Sequence relationships between single repeat units of highly reiterated African Green monkey DNA,” Nucleic Acids Research, vol. 9, no. 1, pp. 169–181, 1981. View at Google Scholar · View at Scopus
- H. F. Willard and J. S. Wayne, “Hierarchical order in chromosome-specific human alpha setellite DNA,” Trends in Genetics, vol. 3, no. 7, pp. 192–198, 1987. View at Google Scholar · View at Scopus
- Z. Larin, M. D. Fricker, and C. Tyler-Smith, “De novo formation of several features of a centromere following introduction of a Y alphoid YAC into mammalian cells,” Human Molecular Genetics, vol. 3, no. 5, pp. 689–695, 1994. View at Google Scholar · View at Scopus
- R. Wevrick and H. F. Willard, “Long-range organization of tandem arrays of α satellite DNA at the centromeres of human chromosomes: high-frequency array-length polymorphism and meiotic stability,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 23, pp. 9394–9398, 1989. View at Publisher · View at Google Scholar · View at Scopus
- J. J. Harrington, G. Van Bokkelen, R. W. Mays, K. Gustashaw, and H. F. Willard, “Formation of de novo centromeres and construction of first-generation human artificial microchromosomes,” Nature Genetics, vol. 15, no. 4, pp. 345–355, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. E. Mejía, A. Alazami, A. Willmott, P. Marschall, E. Levy, W. C. Earnshaw, and Z. Larin, “Efficiency of de novo centromere formation in human artificial chromosomes,” Genomics, vol. 79, no. 3, pp. 297–304, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J.-I. Ohzeki, M. Nakano, T. Okada, and H. Masumoto, “CENP-B box is required for de novo centromere chromatin assembly on human alphoid DNA,” Journal of Cell Biology, vol. 159, no. 5, pp. 765–775, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- H. Masumoto, M. Ikeno, M. Nakano, T. Okazaki, B. Grimes, H. Cooke, and N. Suzuki, “Assay of centromere function using a human artificial chromosome,” Chromosoma, vol. 107, no. 6-7, pp. 406–416, 1998. View at Publisher · View at Google Scholar · View at Scopus
- K. H. A. Choo, “Centromerization,” Trends in Cell Biology, vol. 10, no. 5, pp. 182–188, 2000. View at Publisher · View at Google Scholar · View at Scopus
- D. du Sart, M. R. Cancilla, and M. R. Cancilla, “A functional neo-centromere formed through activation of a latent human centromere and consisting of non-alpha-satellite DNA,” Nature Genetics, vol. 16, no. 2, pp. 144–153, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- T. W. Depinet, J. L. Zackowski, and J. L. Zackowski, “Characterization of neo-centromeres in marker chromosomes lacking detectable alpha-satellite DNA,” Human Molecular Genetics, vol. 6, no. 8, pp. 1195–1204, 1997. View at Publisher · View at Google Scholar · View at Scopus
- W. C. Earnshaw, H. Ratrie III, and G. Stetten, “Visualization of centromere proteins CENP-B and CENP-C on a stable dicentric chromosome in cytological spreads,” Chromosoma, vol. 98, no. 1, pp. 1–12, 1989. View at Google Scholar · View at Scopus
- H. F. Willard, “Neocentromeres and human artificial chromosomes: an unnatural act,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5374–5376, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. W. Yang, C. Pendon, J. Yang, N. Haywood, A. Chand, and W. R. A. Brown, “Human mini-chromosomes with minimal centromeres,” Human Molecular Genetics, vol. 9, no. 12, pp. 1891–1902, 2000. View at Google Scholar · View at Scopus
- A. W. I. Lo, G. C.-C. Liao, M. Rocchi, and K. H. A. Choo, “Extreme reduction of chromosome-specific α-satellite array is unusually common in human chromosome 21,” Genome Research, vol. 9, no. 10, pp. 895–908, 1999. View at Publisher · View at Google Scholar · View at Scopus
- T. A. Ebersole, A. Ross, E. Clark, N. McGill, D. Schindelhauer, H. Cooke, and B. Grimes, “Mammalian artificial chromosome formation from circular alphoid input DNA does not require telomere repeats,” Human Molecular Genetics, vol. 9, no. 11, pp. 1623–1631, 2000. View at Google Scholar · View at Scopus
- M. Ikeno, B. Grimes, and B. Grimes, “Construction of YAC-based mammalian artificial chromosomes,” Nature Biotechnology, vol. 16, no. 5, pp. 431–439, 1998. View at Google Scholar · View at Scopus
- G. Kotzamanis, W. Cheung, H. Abdulrazzak, S. Perez-Luz, S. Howe, H. Cooke, and C. Huxley, “Construction of human artificial chromosome vectors by recombineering,” Gene, vol. 351, pp. 29–38, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- H. F. Willard, “Chromosome manipulation: a systematic approach toward understanding human chromosome structure and function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 14, pp. 6847–6850, 1996. View at Publisher · View at Google Scholar · View at Scopus
- D. T. Burke, G. F. Carle, and M. V. Olson, “Cloning of large segments of exogenous DNA into yeast by means of artificial chromosome vectors,” Science, vol. 236, no. 4803, pp. 806–812, 1987. View at Google Scholar · View at Scopus
- A. Jakobovits, A. L. Moore, L. L. Green, G. J. Vergara, C. E. Maynard-Currie, H. A. Austin, and S. Klapholz, “Germ-line transmission and expression of a human-derived yeast artificial chromosome,” Nature, vol. 362, no. 6417, pp. 255–258, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- A. M. Alazami, J. E. Mejía, and Z. L. Monaco, “Human artificial chromosomes containing chromosome 17 alphoid DNA maintain an active centromere in murine cells but are not stable,” Genomics, vol. 83, no. 5, pp. 844–851, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- B. R. Grimes, D. Schindelhauer, N. I. McGill, A. Ross, T. A. Ebersole, and H. J. Cooke, “Stable gene expression from a mammalian artificial chromosome,” EMBO Reports, vol. 2, no. 10, pp. 910–914, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. E. Mejía, A. Willmott, E. Levy, W. C. Earnshaw, and Z. Larin, “Functional complementation of a genetic deficiency with human artificial chromosomes,” American Journal of Human Genetics, vol. 69, no. 2, pp. 315–326, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. E. Mejía and Z. Larin, “The assembly of large BACs by in vivo recombination,” Genomics, vol. 70, no. 2, pp. 165–170, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. Kakeda, M. Hiratsuka, and M. Hiratsuka, “Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts,” Gene Therapy, vol. 12, no. 10, pp. 852–856, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- A. M. Killary and R. E. K. Fournier, “Microcell fusion,” Methods in Enzymology, vol. 254, pp. 133–152, 1995. View at Publisher · View at Google Scholar · View at Scopus
- H. Hoshiya, Y. Kazuki, and Y. Kazuki, “A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene,” Molecular Therapy, vol. 17, no. 2, pp. 309–317, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- Y. Kazuki, M. Hiratsuka, and M. Hiratsuka, “Complete genetic correction of iPS cells from Duchenne muscular dystrophy,” Molecular Therapy, vol. 18, no. 2, pp. 386–393, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. K. Rudd, R. W. Mays, S. Schwartz, and H. F. Willard, “Human artificial chromosomes with alpha satellite-based de novo centromeres show increased frequency of nondisjunction and anaphase lag,” Molecular and Cellular Biology, vol. 23, no. 21, pp. 7689–7697, 2003. View at Publisher · View at Google Scholar · View at Scopus
- J. M. Spence, W. Mills, K. Mann, C. Huxley, and C. J. Farr, “Increased missegregation and chromosome loss with decreasing chromosome size in vertebrate cells,” Chromosoma, vol. 115, no. 1, pp. 60–74, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. H. Shen, J. W. Yang, J. Yang, C. Pendon, and W. R. A. Brown, “The accuracy of segregation of human mini-chromosomes varies in different vertebrate cell lines, correlates with the extent of centromere formation and provides evidence for a trans-acting centromere maintenance activity,” Chromosoma, vol. 109, no. 8, pp. 524–535, 2000. View at Google Scholar · View at Scopus
- C. R. Sclimenti and M. P. Calos, “Epstein-Barr virus vectors for gene expression and transfer,” Current Opinion in Biotechnology, vol. 9, no. 5, pp. 476–479, 1998. View at Publisher · View at Google Scholar · View at Scopus
- B. Sugden, K. Marsh, and J. Yates, “A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus,” Molecular and Cellular Biology, vol. 5, no. 2, pp. 410–413, 1985. View at Google Scholar · View at Scopus
- J. Yates, N. Warren, D. Reisman, and B. Sugden, “A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 12, pp. 3806–3810, 1984. View at Google Scholar · View at Scopus
- J. L. Yates, N. Warren, and B. Sugden, “Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells,” Nature, vol. 313, no. 6005, pp. 812–815, 1985. View at Google Scholar · View at Scopus
- D. Reisman, J. Yates, and B. Sugden, “A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components,” Molecular and Cellular Biology, vol. 5, no. 8, pp. 1822–1832, 1985. View at Google Scholar · View at Scopus
- S. Lupton and A. J. Levine, “Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells,” Molecular and Cellular Biology, vol. 5, no. 10, pp. 2533–2542, 1985. View at Google Scholar · View at Scopus
- D. R. Rawlins, G. Milman, S. D. Hayward, and G. S. Hayward, “Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region,” Cell, vol. 42, no. 3, pp. 859–868, 1985. View at Google Scholar · View at Scopus
- T. A. Gahn and C. L. Schildkraut, “The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication,” Cell, vol. 58, no. 3, pp. 527–535, 1989. View at Google Scholar · View at Scopus
- D. Reisman and B. Sugden, “trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1,” Molecular and Cellular Biology, vol. 6, no. 11, pp. 3838–3846, 1986. View at Google Scholar · View at Scopus
- J. L. Yates and N. Guan, “Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells,” Journal of Virology, vol. 65, no. 1, pp. 483–488, 1991. View at Google Scholar · View at Scopus
- S. B. Haase and M. P. Calos, “Replication control of autonomously replicating human sequences,” Nucleic Acids Research, vol. 19, no. 18, pp. 5053–5058, 1991. View at Google Scholar · View at Scopus
- P. J. Krysan and M. P. Calos, “Epstein-Barr virus-based vectors that replicate in rodent cells,” Gene, vol. 136, no. 1-2, pp. 137–143, 1993. View at Publisher · View at Google Scholar · View at Scopus
- V. K. Nayyar, K. Shire, and L. Frappier, “Mitotic chromosome interactions of Epstein-Barr nuclear antigen 1 (EBNA1) and human EBNA1-bindingprotein 2 (EBP2),” Journal of Cell Science, vol. 122, no. 23, pp. 4341–4350, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- H. Okayama and P. Berg, “A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells,” Molecular and Cellular Biology, vol. 3, no. 2, pp. 280–289, 1983. View at Google Scholar · View at Scopus
- R. F. Margolskee, P. Kavathas, and P. Berg, “Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells,” Molecular and Cellular Biology, vol. 8, no. 7, pp. 2837–2847, 1988. View at Google Scholar · View at Scopus
- S. Banerjee, E. Livanos, and J.-M. H. Vos, “Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus,” Nature Medicine, vol. 1, no. 12, pp. 1303–1308, 1995. View at Google Scholar · View at Scopus
- D. C. Lei, K. Kunzelmann, and K. Kunzelmann, “Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells,” Gene Therapy, vol. 3, no. 5, pp. 427–436, 1996. View at Google Scholar · View at Scopus
- S. Mücke, A. Polack, and A. Polack, “Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells,” Gene Therapy, vol. 4, no. 2, pp. 82–92, 1997. View at Google Scholar · View at Scopus
- J. M. Young, C. Cheadle, J. S. Foulke Jr., W. N. Drohan, and N. Sarver, “Utilization of an Epstein-Barr virus replicon as a eukaryotic expression vector,” Gene, vol. 62, no. 2, pp. 171–185, 1988. View at Google Scholar · View at Scopus
- G. Cachianes, C. Ho, R. F. Weber, S. R. Williams, D. V. Goeddel, and D. W. Leung, “Epstein-Barr virus-derived vectors for transient and stable expression of recombinant proteins,” BioTechniques, vol. 15, no. 2, pp. 255–258, 1993. View at Google Scholar · View at Scopus
- K. Simpson, A. McGuigan, and C. Huxley, “Stable episomal maintenance of yeast artificial chromosomes in human cells,” Molecular and Cellular Biology, vol. 16, no. 9, pp. 5117–5126, 1996. View at Google Scholar · View at Scopus
- A. Harris, B. D. Young, and B. E. Griffin, “Random associated of Epstein-Barr virus genomes with host cell metaphase chromosome in Burkitt's lymphoma-derived cell lines,” Journal of Virology, vol. 56, no. 1, pp. 328–332, 1985. View at Google Scholar · View at Scopus
- D. Huertas, S. Howe, A. McGuigan, and C. Huxley, “Expression of the human CFTR gene from episomal oriP-EBNA1-YACs in mouse cells,” Human Molecular Genetics, vol. 9, no. 4, pp. 617–629, 2000. View at Google Scholar · View at Scopus
- T. Kaname and C. Huxley, “Simple and efficient vectors for retrofitting BACs and PACs with mammalian neoR and EGFP marker genes,” Gene, vol. 266, no. 1-2, pp. 147–153, 2001. View at Publisher · View at Google Scholar · View at Scopus
- C. Magin-Lachmann, G. Kotzamanis, L. D'Aiuto, H. Cooke, C. Huxley, and E. Wagner, “In vitro and in vivo delivery of intact BAC DNA—comparison of different methods,” Journal of Gene Medicine, vol. 6, no. 2, pp. 195–209, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- C. Magin-Lachman, G. Kotzamanis, L. D'Aiuto, E. Wagner, and C. Huxley, “Retrofitting BACs with G418 resistance, luciferase, and oriP and EBNA-1—new vectors for in vitro and in vivo delivery,” BMC Biotechnology, vol. 3, article no. 2, 2003. View at Publisher · View at Google Scholar
- P. Courvalin, S. Goussard, and C. Grillot-Courvalin, “Gene transfer from bacteria to mammalian cells,” Comptes Rendus de l'Academie des Sciences. Serie III, vol. 318, no. 12, pp. 1207–1212, 1995. View at Google Scholar · View at Scopus
- C. Grillot-Courvalin, S. Goussard, and P. Courvalin, “Wild-type intracellular bacteria deliver DNA into mammalian cells,” Cellular Microbiology, vol. 4, no. 3, pp. 177–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
- W. Schaffner, “Direct transfer of cloned genes from bacteria to mammalian cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 4 I, pp. 2163–2167, 1980. View at Google Scholar · View at Scopus
- C. Grillot-Courvalin, S. Goussard, and P. Courvalin, “Bacteria as gene delivery vectors for mammalian cells,” Current Opinion in Biotechnology, vol. 10, no. 5, pp. 477–481, 1999. View at Publisher · View at Google Scholar · View at Scopus
- S. Weiss and T. Chakraborty, “Transfer of eukaryotic expression plasmids to mammalian host cells by bacterial carriers,” Current Opinion in Biotechnology, vol. 12, no. 5, pp. 467–472, 2001. View at Publisher · View at Google Scholar · View at Scopus
- D. Q. Xu, L. Zhang, D. J. Kopecko, L. Gao, Y. Shao, B. Guo, and L. Zhao, “Bacterial delivery of siRNAs: a new approach to solid tumor therapy,” Methods in Molecular Biology, vol. 487, pp. 161–187, 2009. View at Google Scholar · View at Scopus
- M. Chamekh, A. Phalipon, R. Quertainmont, I. Salmon, P. Sansonetti, and A. Allaoui, “Delivery of biologically active anti-inflammatory cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion apparatus,” Journal of Immunology, vol. 180, no. 6, pp. 4292–4298, 2008. View at Google Scholar · View at Scopus
- J. Stritzker, S. Pilgrim, A. A. Szalay, and W. Goebel, “Prodrug converting enzyme gene delivery by L. monocytogenes,” BMC Cancer, vol. 8, article no. 94, 2008. View at Publisher · View at Google Scholar · View at PubMed
- A. Al-Mariri, A. Tibor, P. Lestrate, P. Mertens, X. De Bolle, and J.-J. Letesson, “Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen,” Infection and Immunity, vol. 70, no. 4, pp. 1915–1923, 2002. View at Publisher · View at Google Scholar · View at Scopus
- T. Sasaki, M. Fujimori, Y. Hamaji, Y. Hama, K.-I. Ito, J. Amano, and S. Taniguchi, “Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats,” Cancer Science, vol. 97, no. 7, pp. 649–657, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- P. Michl and T. M. Gress, “Bacteria and bacterial toxins as therapeutic agents for solid tumors,” Current Cancer Drug Targets, vol. 4, no. 8, pp. 689–702, 2004. View at Publisher · View at Google Scholar · View at Scopus
- C.-H. Lee, C.-L. Wu, and A.-L. Shiau, “Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model,” Cancer Gene Therapy, vol. 12, no. 2, pp. 175–184, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- R. M. Ryan, J. Green, and J. Green, “Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors,” Gene Therapy, vol. 16, no. 3, pp. 329–339, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- Z. Li, J. Fallon, J. Mandeli, J. Wetmur, and S. L. C. Woo, “A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer,” Journal of the National Cancer Institute, vol. 100, no. 19, pp. 1389–1400, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. Theys, W. Landuyt, S. Nuyts, L. Van Mellaert, A. Van Oosterom, P. Lambin, and J. Anné, “Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum,” Cancer Gene Therapy, vol. 8, no. 4, pp. 294–297, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J.-F. Ning, W. Zhu, J.-P. Xu, C.-Y. Zheng, and X.-L. Meng, “Oral delivery of DNA vaccine encoding VP28 against white spot syndrome virus in crayfish by attenuated Salmonella typhimurium,” Vaccine, vol. 27, no. 7, pp. 1127–1135, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- A. Abdul-Wahid and G. Faubert, “Mucosal delivery of a transmission-blocking DNA vaccine encoding Giardia lamblia CWP2 by Salmonella typhimurium bactofection vehicle,” Vaccine, vol. 25, no. 50, pp. 8372–8383, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- K. Sandvig and B. van Deurs, “Delivery into cells: lessons learned from plant and bacterial toxins,” Gene Therapy, vol. 12, no. 11, pp. 865–872, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- C. Grillot-Courvalin, S. Goussard, F. Huetz, D. M. Ojcius, and P. Courvalin, “Functional gene transfer from intracellular bacteria to mammalian cells,” Nature Biotechnology, vol. 16, no. 9, pp. 862–866, 1998. View at Google Scholar · View at Scopus
- I. Castagliuolo, E. Beggiao, and E. Beggiao, “Engineered E. coli delivers therapeutic genes to the colonic mucosa,” Gene Therapy, vol. 12, no. 13, pp. 1070–1078, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- R. R. Isberg, D. L. Voorhis, and S. Falkow, “Identification of invasin: a protein that allows enteric bacteria to penetrate cultured mammalian cells,” Cell, vol. 50, no. 5, pp. 769–778, 1987. View at Google Scholar · View at Scopus
- J. M. Leong, R. S. Fournier, and R. R. Isberg, “Identification of the integrin binding domain of the Yersinia pseudotuberculosis invasin protein,” EMBO Journal, vol. 9, no. 6, pp. 1979–1989, 1990. View at Google Scholar · View at Scopus
- J. M. Leong, P. E. Morrissey, and R. R. Isberg, “A 76-amino acid disulfide loop in the Yersinia pseudotuberculosis invasin protein is required for integrin receptor recognition,” Journal of Biological Chemistry, vol. 268, no. 27, pp. 20524–20532, 1993. View at Google Scholar · View at Scopus
- R. R. Isberg and S. Falkow, “A single genetic locus encoded by Yersinia pseudotuberculosis permits invasion of cultured animal cells by Escherichia coli K-12,” Nature, vol. 317, no. 6034, pp. 262–264, 1985. View at Google Scholar · View at Scopus
- J. E. Alouf, “Cholesterol-binding cytolytic protein toxins,” International Journal of Medical Microbiology, vol. 290, no. 4-5, pp. 351–356, 2000. View at Google Scholar · View at Scopus
- C. Geoffroy, J.-L. Gaillard, J. E. Alouf, and P. Berche, “Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes,” Infection and Immunity, vol. 55, no. 7, pp. 1641–1646, 1987. View at Google Scholar · View at Scopus
- P. Cossart, M. F. Vicente, J. Mengaud, F. Baquero, J. C. Perez-Diaz, and P. Berche, “Listeriolysin O is essential for virulence of Listeria monocytogenes: direct evidence obtained by gene complementation,” Infection and Immunity, vol. 57, no. 11, pp. 3629–3636, 1989. View at Google Scholar · View at Scopus
- A. Laner, S. Goussard, and S. Goussard, “Bacterial transfer of large functional genomic DNA into human cells,” Gene Therapy, vol. 12, no. 21, pp. 1559–1572, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- K. Narayanan and P. E. Warburton, “DNA modification and functional delivery into human cells using Escherichia coli DH10B,” Nucleic Acids Research, vol. 31, no. 9, article no. e51, 2003. View at Google Scholar
- S. Pérez-Luz, H. Abdulrazzak, C. Grillot-Courvalin, and C. Huxley, “Factor VIII mRNA expression from a BAC carrying the intact locus made by homologous recombination,” Genomics, vol. 90, no. 5, pp. 610–619, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- K. L. Poffenberger, E. Tabares, and B. Roizman, “Characterization of a viable, noninverting herpes simplex virus 1 genome derived by insertion and deletion of sequences at the junction of components L and S,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 9 I, pp. 2690–2694, 1983. View at Google Scholar · View at Scopus
- A. Oehmig, C. Fraefel, X. O. Breakefield, and M. Ackermann, “Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus,” Current Gene Therapy, vol. 4, no. 4, pp. 385–408, 2004. View at Google Scholar · View at Scopus
- R. Wade-Martins, Y. Saeki, and E. A. Chiocca, “Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells,” Molecular Therapy, vol. 7, no. 5, pp. 604–612, 2003. View at Publisher · View at Google Scholar · View at Scopus
- L. Müller, O. Saydam, Y. Saeki, I. Heid, and C. Fraefel, “Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons,” Journal of Virological Methods, vol. 123, no. 1, pp. 65–72, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- A. L. Epstein, P. Marconi, R. Argnani, and R. Manservigi, “HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy,” Current Gene Therapy, vol. 5, no. 5, pp. 445–458, 2005. View at Publisher · View at Google Scholar · View at Scopus
- P. A. Johnson, A. Miyanohara, F. Levine, T. Cahill, and T. Friedmann, “Cytotoxicity of a replication-defective mutant of herpes simplex virus type I,” Journal of Virology, vol. 66, no. 5, pp. 2952–2965, 1992. View at Google Scholar · View at Scopus
- Y. Saeki, C. Fraefel, T. Ichikawa, X. O. Breakefield, and E. A. Chiocca, “Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome,” Molecular Therapy, vol. 3, no. 4, pp. 591–601, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- Y. Saeki, T. Ichikawa, and T. Ichikawa, “Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors,” Human Gene Therapy, vol. 9, no. 18, pp. 2787–2794, 1998. View at Google Scholar · View at Scopus
- M. Agudo, J. Luis Trejo, F. Lim, J. Avila, I. Torres-Alemän, J. Diaz-Nido, and F. Wandosell, “Highly efficient and specific gene transfer to purkinje cells in vivo using a herpes simplex virus I amplicon,” Human Gene Therapy, vol. 13, no. 5, pp. 665–674, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- B. K. Berges, J. H. Wolfe, and N. W. Fraser, “Transduction of brain by herpes simplex virus vectors,” Molecular Therapy, vol. 15, no. 1, pp. 20–29, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- D. J. Fink, N. A. DeLuca, W. F. Goins, and J. C. Glorioso, “Gene transfer to neurons using herpes simplex virus-based vectors,” Annual Review of Neuroscience, vol. 19, pp. 265–287, 1996. View at Google Scholar · View at Scopus
- A. R. Frampton Jr., W. F. Goins, K. Nakano, E. A. Burton, and J. C. Glorioso, “HSV trafficking and development of gene therapy vectors with applications in the nervous system,” Gene Therapy, vol. 12, no. 11, pp. 891–901, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- A. Oehmig, C. Fraefel, and X. O. Breakefield, “Update on herpesvirus amplicon vectors,” Molecular Therapy, vol. 10, no. 4, pp. 630–643, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- B. K. Jin, M. Belloni, and M. Belloni, “Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector,” Human Gene Therapy, vol. 7, no. 16, pp. 2015–2024, 1996. View at Google Scholar · View at Scopus
- D. Moralli, K. M. Simpson, R. Wade-Martins, and Z. L. Monaco, “A novel human artificial chromosome gene expression system using herpes simplex virus type 1 vectors,” EMBO Reports, vol. 7, no. 9, pp. 911–918, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- E. M. Borst and M. Messerle, “Construction of a cytomegalovirus-based amplicon: a vector with a unique transfer capacity,” Human Gene Therapy, vol. 14, no. 10, pp. 959–970, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- P. M. Mannucci and E. G. D. Tuddenham, “The hemophilias—from royal genes to gene therapy,” New England Journal of Medicine, vol. 344, no. 23, pp. 1773–1779, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- H. Chao, R. J. Samulski, D. A. Bellinger, P. E. Monahan, T. C. Nichols, and C. E. Walsh, “Persistent expression of canine factor IX in hemophilia B canines,” Gene Therapy, vol. 6, no. 10, pp. 1695–1704, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- V. Cherington et al., “Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion,” Human Gene Therapy, vol. 9, no. 10, pp. 1397–1407, 1998. View at Google Scholar
- B. Fang, R. C. Eisensmith, and R. C. Eisensmith, “Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression,” Human Gene Therapy, vol. 6, no. 8, pp. 1039–1044, 1995. View at Google Scholar · View at Scopus
- G. P. Niemeyer, R. W. Herzog, and R. W. Herzog, “Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy,” Blood, vol. 113, no. 4, pp. 797–806, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. A. Kay and K. High, “Gene therapy for the hemophilias,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 18, pp. 9973–9975, 1999. View at Publisher · View at Google Scholar · View at Scopus
- S. Connelly, T. A. G. Smith, and T. A. G. Smith, “In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice,” Human Gene Therapy, vol. 6, no. 2, pp. 185–193, 1995. View at Google Scholar · View at Scopus
- M. K. L. Chuah, T. Vandendriessche, and R. A. Morgan, “Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A,” Human Gene Therapy, vol. 6, no. 11, pp. 1363–1377, 1995. View at Google Scholar · View at Scopus
- D. L. Eaton, P. E. Hass, and L. Riddle, “Characterization of recombinant human factor VIII,” Journal of Biological Chemistry, vol. 262, no. 7, pp. 3285–3290, 1987. View at Google Scholar · View at Scopus
- J. J. Toole et al., “A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 16, pp. 5939–5942, 1986. View at Google Scholar
- D. L. Eaton, W. I. Wood, and W. I. Wood, “Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule,” Biochemistry, vol. 25, no. 26, pp. 8343–8347, 1986. View at Google Scholar · View at Scopus
- Y. Yang and J. M. Wilson, “Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo,” Journal of Immunology, vol. 155, no. 5, pp. 2564–2570, 1995. View at Google Scholar · View at Scopus
- S. Connelly, J. M. Gardner, R. M. Lyons, A. McClelland, and M. Kaleko, “Sustained expression of therapeutic levels of human factor VIII in mice,” Blood, vol. 87, no. 11, pp. 4671–4677, 1996. View at Google Scholar · View at Scopus
- C. Balagué, J. Zhou, and J. Zhou, “Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector,” Blood, vol. 95, no. 3, pp. 820–828, 2000. View at Google Scholar · View at Scopus
- S. Connelly, J. Mount, A. Mauser, J. M. Gardner, M. Kaleko, A. McClelland, and C. D. Lothrop Jr., “Complete short-term correction of canine hemophilia A by in vivo gene therapy,” Blood, vol. 88, no. 10, pp. 3846–3853, 1996. View at Google Scholar · View at Scopus
- J. L. Andrews, P. S. Shirley, and P. S. Shirley, “Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector,” Human Gene Therapy, vol. 13, no. 11, pp. 1331–1336, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- B. D. Brown, C. X. Shi, S. Powell, D. Hurlbut, F. L. Graham, and D. Lillicrap, “Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A,” Blood, vol. 103, no. 3, pp. 804–810, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. L. Andrews, M. J. Kadan, M. I. Gorziglia, M. Kaleko, and S. Connelly, “Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII,” Molecular Therapy, vol. 3, no. 3, pp. 329–336, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- R. C. Hoeben, R. C. M. Van Der Jagt, and R. C. M. Van Der Jagt, “Expression of functional factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer,” Journal of Biological Chemistry, vol. 265, no. 13, pp. 7318–7323, 1990. View at Google Scholar · View at Scopus
- D. I. Israel and R. J. Kaufman, “Retroviral-mediated transfer and amplification of a functional human factor VIII gene,” Blood, vol. 75, no. 5, pp. 1074–1080, 1990. View at Google Scholar · View at Scopus
- M. K. L. Chuah, H. Brems, V. Vanslembrouck, D. Collen, and T. VandenDriessche, “Bone marrow stromal cells as targets for gene therapy of hemophilia A,” Human Gene Therapy, vol. 9, no. 3, pp. 353–365, 1998. View at Google Scholar · View at Scopus
- F. J. Fallaux, R. C. Hoeben, S. J. Cramer, D. J. M. Van Den Wollenberg, E. Briët, H. Van Ormondt, and A. J. Van Der Eb, “The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate,” Molecular and Cellular Biology, vol. 16, no. 8, pp. 4264–4272, 1996. View at Google Scholar · View at Scopus
- R. C. Hoeben, F. J. Fallaux, S. J. Cramer, D. J. M. Van den Wollenberg, H. Van Ormondt, E. Briet, and A. J. Van der Eb, “Expression of the blood-clotting factor-VIII cDNA is repressed by a transcriptional silencer located in its coding region,” Blood, vol. 85, no. 9, pp. 2447–2454, 1995. View at Google Scholar · View at Scopus
- D. D. Koeberl, C. L. Halbert, A. Krumm, and A. D. Miller, “Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation,” Human Gene Therapy, vol. 6, no. 4, pp. 469–479, 1995. View at Google Scholar · View at Scopus
- C. M. Lynch, D. I. Israel, R. J. Kaufman, and A. D. Miller, “Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production,” Human Gene Therapy, vol. 4, no. 3, pp. 259–272, 1993. View at Google Scholar · View at Scopus
- J. Byun, S.-H. Kim, J. Mook Kim, S. Shin Yu, P. D. Robbins, J. Yim, and S. Kim, “Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy,” Gene Therapy, vol. 3, no. 9, pp. 780–788, 1996. View at Google Scholar · View at Scopus
- V. J. Dwarki, P. Belloni, and P. Belloni, “Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 4, pp. 1023–1027, 1995. View at Publisher · View at Google Scholar · View at Scopus
- T. VandenDriessche, V. Vanslembrouck, I. Goovaerts, H. Zwinnen, M.-L. Vanderhaeghen, D. Collen, and M. K. L. Chuah, “Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 18, pp. 10379–10384, 1999. View at Publisher · View at Google Scholar · View at Scopus
- C. S. Stein, Y. Kang, and Y. Kang, “In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors,” Molecular Therapy, vol. 3, no. 6, pp. 850–856, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- N. A. Kootstra, R. Matsumura, and I. M. Verma, “Efficient production of human FVIII in hemophilic mice using lentiviral vectors,” Molecular Therapy, vol. 7, no. 5, pp. 623–631, 2003. View at Publisher · View at Google Scholar · View at Scopus
- H. Chao, L. Sun, A. Bruce, X. Xiao, and C. E. Walsh, “Expression of human factor VIII by splicing between dimerized AAV vectors,” Molecular Therapy, vol. 5, no. 6, pp. 716–722, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- C. D. Scallan, D. Lillicrap, and D. Lillicrap, “Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector,” Blood, vol. 102, no. 6, pp. 2031–2037, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- S. Youjin and Y. Jun, “The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy,” Biotechnology Letters, vol. 31, no. 3, pp. 321–328, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- D. A. Roth, N. E. Tawa Jr., J. M. O'Brien, D. A. Treco, and R. F. Selden, “Nonviral transfer of the gene encoding coagulation factor viii in patients with severe hemophilia A,” New England Journal of Medicine, vol. 344, no. 23, pp. 1735–1742, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. S. Powell, M. V. Ragni, and M. V. Ragni , “Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion,” Blood, vol. 102, no. 6, pp. 2038–2045, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. K. L. Chuah, D. Collen, and T. VandenDriassche, “Clinical gene transfer studies for hemophilia A,” Seminars in Thrombosis and Hemostasis, vol. 30, no. 2, pp. 249–256, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- G. Kotzamanis and C. Huxley, “Recombining overlapping BACs into a single larger BAC,” BMC Biotechnology, vol. 4, article no. 1, 2004. View at Publisher · View at Google Scholar · View at PubMed
- V. Campuzano, L. Montermini, and L. Montermini, “Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion,” Science, vol. 271, no. 5254, pp. 1423–1427, 1996. View at Google Scholar · View at Scopus
- N. Sakamoto, P. D. Chastain, P. Parniewski, K. Ohshima, M. Pandolfo, J. D. Griffith, and R. D. Wells, “Sticky DNA: self-association properties of long GAA · TTC repeats in R · R · Y triplex structures from Friedreich's ataxia,” Molecular Cell, vol. 3, no. 4, pp. 465–475, 1999. View at Publisher · View at Google Scholar · View at Scopus
- P. I. Patel and G. Isaya, “Friedreich ataxia: from GAA triplet-repeat expansion to frataxin deficiency,” American Journal of Human Genetics, vol. 69, no. 1, pp. 15–24, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- V. Campuzano, L. Montermini, and L. Montermini, “Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes,” Human Molecular Genetics, vol. 6, no. 11, pp. 1771–1780, 1997. View at Publisher · View at Google Scholar · View at Scopus
- M. Babcock, D. De Silva, and D. De Silva, “Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin,” Science, vol. 276, no. 5319, pp. 1709–1712, 1997. View at Publisher · View at Google Scholar · View at Scopus
- J. Adamec, F. Rusnak, W. G. Owen, S. Naylor, L. M. Benson, A. M. Gacy, and G. Isaya, “Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia,” American Journal of Human Genetics, vol. 67, no. 3, pp. 549–562, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- O. Stehling, H. Elsässer, B. Brückel, U. Mühlenhoff, and R. Lill, “Iron-sulfur protein maturation in human cells: evidence for a function of frataxin,” Human Molecular Genetics, vol. 13, no. 23, pp. 3007–3015, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. Ristow, M. F. Pfister, and M. F. Pfister, “Frataxin activates mitochondrial energy conversion and oxidative phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12239–12243, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- H. Koutnikova, V. Campuzano, F. Foury, P. Dollé, O. Cazzalini, and M. Koenig, “Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin,” Nature Genetics, vol. 16, no. 4, pp. 345–351, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. Cossée, H. Puccio, and H. Puccio, “Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation,” Human Molecular Genetics, vol. 9, no. 8, pp. 1219–1226, 2000. View at Google Scholar · View at Scopus
- H. Puccio, D. Simon, and D. Simon, “Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits,” Nature Genetics, vol. 27, no. 2, pp. 181–186, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- D. Simon, H. Seznec, and H. Seznec, “Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia,” Journal of Neuroscience, vol. 24, no. 8, pp. 1987–1995, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- C. J. Miranda, M. M. Santos, and M. M. Santos, “Frataxin knockin mouse,” FEBS Letters, vol. 512, no. 1–3, pp. 291–297, 2002. View at Publisher · View at Google Scholar · View at Scopus
- S. Al-Mahdawi, R. M. Pinto, and R. M. Pinto, “GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology,” Genomics, vol. 88, no. 5, pp. 580–590, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. Pandolfo, “Drug insight: antioxidant therapy in inherited ataxias,” Nature Clinical Practice Neurology, vol. 4, no. 2, pp. 86–96, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- F. Acquaviva, I. Castaldo, and I. Castaldo, “Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression,” Cerebellum, vol. 7, no. 3, pp. 360–365, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- S. Boesch, B. Sturm, S. Hering, H. Goldenberg, W. Poewe, and B. Scheiber-Mojdehkar, “Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin,” Annals of Neurology, vol. 62, no. 5, pp. 521–524, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- D. Herman, K. Jenssen, R. Burnett, E. Soragni, S. L. Perlman, and J. M. Gottesfeld, “Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia,” Nature Chemical Biology, vol. 2, no. 10, pp. 551–558, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- M. Rai, “HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model,” PLoS One, vol. 3, no. 4, article no. e1958, 2008. View at Google Scholar
- L. Pianese, M. Turano, and M. Turano, “Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 7, pp. 1061–1063, 2004. View at Publisher · View at Google Scholar · View at Scopus
- J. Fleming, A. Spinoulas, and A. Spinoulas, “Partial correction of sensitivity to oxidant stress in Friedreich ataxia patient fibroblasts by frataxin-encoding adeno-associated virus and lentivirus vectors,” Human Gene Therapy, vol. 16, no. 8, pp. 947–956, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- F. Lim, G. M. Palomo, C. Mauritz, A. Giménez-Cassina, B. Illana, F. Wandosell, and J. Díaz-Nido, “Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector,” Molecular Therapy, vol. 15, no. 6, pp. 1072–1078, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- S. Gomez-Sebastian, A. Gimenez-Cassina, J. Diaz-Nido, F. Lim, and R. Wade-Martins, “Infectious delivery and expression of a 135kb human FRDA genomic DNA locus complements friedreich's ataxia deficiency in human cells,” Molecular Therapy, vol. 15, no. 2, pp. 248–254, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- R. Wade-Martins, E. R. Smith, E. Tyminski, E. A. Chiocca, and Y. Saeki, “An infectious transfer and expression system for genomic DNA loci in human and mouse cells,” Nature Biotechnology, vol. 19, no. 11, pp. 1067–1070, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
- J. C. Glorioso and D. J. Fink, “Herpes vector-mediated gene transfer in the treatment of chronic pain,” Molecular Therapy, vol. 17, no. 1, pp. 13–18, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus